Ito Hospital, 4-3-6 Jingumae, Shibuya-ku,Tokyo, Japan.
Br J Haematol. 2011 Apr;153(2):236-43. doi: 10.1111/j.1365-2141.2011.08606.x. Epub 2011 Mar 4.
There are few large-scale reports of primary thyroid lymphoma (PTL). This study clinically and pathologically reviewed 171 patients with PTL and 24,553 patients with Hashimoto's disease at Ito Hospital between January 1990 and December 2004, to investigate the clinical features and the treatment outcomes of PTL. The median age of the patients with PTL was 67 years (range, 27-90 years). The pathological diagnosis of PTL patients included diffuse large B-cell lymphoma (DLBCL) (n=74), DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma (n=13), MALT lymphoma (n=80) and others (n=4). Of the 167 patients with B-cell lymphoma, treatment included combined modality therapy (CMT) (n=95), radiation therapy (RT) alone (n=60) and chemotherapy alone (n=6). Information on treatment was not available in six patients. Information on treatment response was available in 154 patients; 149 patients (97%) responded to treatment. According to the institutional treatment strategy of Ito Hospital, 45 of 54 patients with stage IE disease received RT alone, and 87 of 113 stage IIE patients received CMT. The 5-year overall survival rate was 85% (95% confidence interval, 79-91%). This study demonstrated that PTL showed good response to radiotherapy and chemotherapy and had a favourable prognosis.
原发性甲状腺淋巴瘤(PTL)的大规模报道较少。本研究对 Ito 医院 1990 年 1 月至 2004 年 12 月期间的 171 例 PTL 患者和 24553 例桥本甲状腺炎患者进行了临床和病理回顾,以探讨 PTL 的临床特征和治疗结果。PTL 患者的中位年龄为 67 岁(范围为 27-90 岁)。PTL 患者的病理诊断包括弥漫性大 B 细胞淋巴瘤(DLBCL)(n=74)、DLBCL 伴黏膜相关淋巴组织(MALT)淋巴瘤(n=13)、MALT 淋巴瘤(n=80)和其他(n=4)。在 167 例 B 细胞淋巴瘤患者中,治疗包括联合治疗(CMT)(n=95)、单独放疗(RT)(n=60)和单独化疗(n=6)。6 例患者的治疗信息不可用。154 例患者的治疗反应信息可用;149 例患者(97%)对治疗有反应。根据 Ito 医院的机构治疗策略,54 例 IE 期疾病患者中有 45 例单独接受 RT,113 例 IIE 期疾病患者中有 87 例接受 CMT。5 年总生存率为 85%(95%置信区间,79-91%)。本研究表明,PTL 对放化疗反应良好,预后良好。